This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (66)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Pathology & Laboratory Medicine  • Sports Medicine  • Randomized Controlled Trial  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Don H. Catlin, MD; Benjamin Z. Leder, MD; Brian Ahrens; Borislav Starcevic, MS; Caroline K. Hatton, PhD; Gary A. Green, MD; Joel S. Finkelstein, MD

JAMA. 2000;284:2618-2621.

Context  Several anabolic steroids are sold over-the-counter (OTC) in the United States, and their production is not regulated by the US Food and Drug Administration. Reports have suggested that use of these supplements can cause positive urine test results for metabolites of the prohibited steroid nandrolone.

Objectives  To assess the content and purity of OTC androstenedione and to determine if androstenedione and 19-norandrostenedione administration causes positive urine test results for 19-norandrosterone, a nandrolone metabolite.

Design  Randomized controlled trial of androstenedione, open-label trial of 19-norandrostenedione, and mass spectrometry of androstenedione preparations, conducted between October 1998 and April 2000.

Setting  Outpatient facility of a university hospital.

Participants  A total of 41 healthy men aged 20 to 44 years.

Intervention  Participants were randomly assigned to receive oral androstenedione, 100 mg/d (n = 13) or 300 mg/d (n = 11) for 7 days, or no androstenedione (n = 13); in addition, 4 patients received 10 µg of 19-norandrostenedione.

Main Outcome Measures  Content of OTC androstenedione preparations; level of 19-norandrosterone in urine samples, determined by mass spectrometry, compared among the 3 randomized groups at day 1 and day 7, and among the participants who received 19-norandrostenedione from October 1998 to April 2000.

Results  All urine samples from participants treated with androstenedione contained 19-norandrosterone, while no samples from the no-androstenedione group did. Urinary concentrations were averaged for day 1 vs day 7 measurements; mean (SD) 19-norandrosterone concentrations in the 100-mg/d and 300-mg/d groups were 3.8 (2.5) ng/mL and 10.2 (6.9) ng/mL, respectively (P = .006). The 19-norandrosterone content exceeded the cutoff for reporting positive cases (>2.0 ng/mL) in 20 of 24. The androstenedione preparation used was pure at a sensitivity of 0.1%, but at 0.001% 19-norandrostenedione was found. For the 4 participants to whom 10 µg of 19-norandrostenedione was administered, 19-norandrosterone was found in all urine samples. Of 7 brands of androstenedione analyzed at the 1% level, 1 contained no androstenedione, 1 contained 10 mg of testosterone, and 4 more contained 90% or less of the amount stated on the label.

Conclusion  Our study suggests that trace contamination of androstenedione with 19-norandrostenedione is sufficient to cause urine test results positive for 19-norandrosterone, the standard marker for nandrolone use. Oral steroid doses as small as 10 µg are absorbed and excreted in urine. Some brands of androstenedione are grossly mislabeled. Careful analysis of androstenedione preparations is recommended in all studies of its biological effects.

Author Affiliations: Departments of Molecular and Medical Pharmacology (UCLA Olympic Analytical Laboratory) (Drs Catlin and Hatton and Messrs Ahrens and Starcevic), Medicine (Dr Catlin), and Family Medicine (Dr Green), University of California, Los Angeles; and Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Drs Leder and Finkelstein).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

November 22/29, 2000
JAMA. 2000;284(20):2657-2658.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Doping Control for the Team Physician: A Review of Drug Testing Procedures in Sport
Green
Am J Sports Med 2006;34:1690-1698.
ABSTRACT | FULL TEXT  

QUANTITATIVE DETERMINATION OF METABOLIC PRODUCTS OF 19-NORANDROSTENEDIOL IN HUMAN PLASMA USING GAS CHROMATOGRAPHY/MASS SPECTROMETRY
Schrader et al.
Drug Metab. Dispos. 2006;34:1328-1335.
ABSTRACT | FULL TEXT  

Significance of 19-norandrosterone in athletes' urine samples
Ayotte
Br. J. Sports. Med. 2006;40:i25-i29.
ABSTRACT | FULL TEXT  

Cardiovascular Toxicities of Performance-Enhancing Substances in Sports
Dhar et al.
Mayo Clin Proc. 2005;80:1307-1315.
ABSTRACT  

Pharmacokinetic Evaluation of Three Different Intramuscular Doses of Nandrolone Decanoate: Analysis of Serum and Urine Samples in Healthy Men
Bagchus et al.
J. Clin. Endocrinol. Metab. 2005;90:2624-2630.
ABSTRACT | FULL TEXT  

Effects of Oral Administration of Androstenedione on Plasma Androgens in Young Women Using Hormonal Contraception
Bassindale et al.
J. Clin. Endocrinol. Metab. 2004;89:6030-6038.
ABSTRACT | FULL TEXT  

[13C]Nandrolone Excretion in Trained Athletes: Interindividual Variability in Metabolism
Baume et al.
Clin. Chem. 2004;50:355-364.
ABSTRACT | FULL TEXT  

Use and Effectiveness of Performance-Enhancing Substances
Boyce
Journal of Pharmacy Practice 2003;16:22-36.
ABSTRACT  

A Short Course on the Food and Drug Administration: What You Should Know
Fourcroy
J Androl 2002;23:754-756.
FULL TEXT  

Urine nandrolone metabolites: false positive doping test?
Kohler and Lambert
Br. J. Sports. Med. 2002;36:325-329.
ABSTRACT | FULL TEXT